Table 1 Demography and clinical characteristics of patients between the two groups
Seroma group (n= 21) | Non-seroma group (n= 107) | P value | |
|---|---|---|---|
Age (years) | 48.2±16.3 | 46.9±11.6 | 0.664 |
Sex (n, %) | 0.805 | ||
Male | 17 (81.0%) | 89 (83.2%) | |
Female | 4 (19.0%) | 18 (16.8%) | |
Smoking (n, %) | 5 (23.8%) | 11 (10.3%) | 0.140 |
BMI (kg/m2) | 24.1±2.4 | 20.9±2.3 | <0.001 |
Hernia location | 0.346 | ||
Left side | 6 (28.6%) | 24 (22.4%) | |
Right side | 12 (57.1%) | 76 (71.0%) | |
Bilateral sides | 3 (14.3%) | 7 (6.5%) | |
Type of hernia (n, %) | <0.001 | ||
Direct hernia | 10 (47.6%) | 12 (11.2%) | |
Indirect hernia | 11 (52.4%) | 95 (88.8%) | |
Scrotal hernia (n, %) | 4 (19.0%) | 9 (8.4%) | 0.226 |
Hernial orifice size (cm) | 2.8±0.7 | 1.8±0.6 | <0.001 |
Hernial sac size (cm) | 3.0±0.8 | 3.0±0.8 | 0.986 |
Comorbidity (n, %) | 0.263 | ||
Hypertension | 4 (19.0%) | 20 (18.7%) | |
COPD | 1 (4.8%) | 12 (11.2%) | |
Renal insufficiency | 5 (23.8%) | 12 (11.2%) | |
Diabetes | 6 (28.6%) | 19 (17.8%) | |
None | 5 (23.8%) | 44 (41.1%) | |
Preoperative medication | 0.106 | ||
Antiplatelet therapy | 4 (19.0%) | 9 (8.4%) | |
Anticoagulation therapy | 6 (28.6%) | 18 (16.8%) | |
None | 11 (52.4%) | 85 (79.4%) | |
Recurrent hernia (n, %) | 2 (9.5%) | 9 (8.4%) | 1.000 |
Surgical procedure | <0.001 | ||
TEP (n, %) | 15 (71.4%) | 12 (11.2%) | |
TAPP (n, %) | 6 (28.6%) | 95 (88.8%) | |
Operative time (min) | 68.6±10.3 | 65.4±11.9 | 0.253 |
Intraoperative bleeding (mL) | 10.2±6.7 | 11.9±4.8 | 0.195 |
Hernial sac treatment | 0.011 | ||
Reduction | 9 (42.9%) | 19 (17.8%) | |
Transection | 12 (57.1%) | 88 (82.2%) | |
Postoperative external compression | 3 (14.3%) | 11 (10.3%) | 0.712 |
PSAL (g/L) | 31.9±6.7 | 39.6±6.2 | <0.001 |